PubMed Health⌕ Search

Biomedical subjects

V P Eijsvoogel

Publications and source records attributed to V P Eijsvoogel.

At least 19 recordsLinked to original sources
PubMed1982

Identification of human CML target. HLA-B locus (B12) antigen variants defined by CTL generated between B locus-identical (B12) responder-stimulator pairs.

The genetics of human CML targets were studied by seven CTL generated in combinations iun which the responder/stimulator difference was limited to one (or two) HLA-A, -B, or -C antigens. Unstimulated peripheral blood lymphocytes were used as targets. CTL sensitized against antigens A11, Aw31, or B17 lysed all cells bearing the respective target from a large panel of cells from unrelated individuals. Hence, at least one CTL clone was directed against the HLA antigen molecule. However, all CTL also exerted cross-kill to cells not sharing the stimulating HLA antigen. For two CTL, the target of the cross-kill was not clarified. Five CTL were found where the cross-kill was directed against antigen HLA-B12 (Bw44 and Bw45). All these cTL were generated in R/S pairs identical for B locus antigens (Bw44/Bw35 heterozygotes). The individual CTL lysed different parts of the panel of B12-positive target cells. The interpretation is that these CTL detect subtypes of HLA antigens, but alternative possibilities are also considered. Four B12 subtypes are described, tentatively designated as B12-related CML targets. Identification of HLA-B-related CML targets represent CML "typing" of HLA-antigen differences that were not detected serologically. The subtypes can now be tested for their possible functional significance.

B-Lymphocytes↗
PubMed1979

Cellular immunity in patients with the Wiskott-Aldrich syndrome before and after administration of transfer factor: a follow-up study.

Four patients with Wiskott-Aldrich syndrome were treated with transfer factor (TF), in an attempt to improve their clinical condition. Before and during treatment, cellular reactivity was followed in vivo (delayed type skin reactivity) and in vitro (lymphocyte transformation). In all patients positive skin reactions were occasionally observed during TF treatment. The lymphocyte reactivity in vitro to phytohaemagglutinin (PHA) was slightly diminished, the responding capacity of the mixed lymphocyte culture (MLC) severely impaired and the response to bacterial, viral and fungal antigens absent before and during TF treatment. No clinical improvement was observed after large doses of TF. No correlation between skin test reversal and TF administration was found, and lymphocyte transformation in vitro did not improve. Subsequently, a double blind trial, in which we compared the effect of TF and placebo, was carried out in these patients, which revealed no effect of TF therapy. It is concluded that the results of treatment with TF in these patients are highly controversial.

Clinical Trials as Topic↗
PubMed1977

Effect of a human serum thymic factor on hydrocortisone-treated thymocytes.

A human serum thymic factors (SF) stimulated cyclic adenosine-3' ,5'-monophosphate (cAMP) synthesis in normal mouse thymocytes. Such stimulation was no longer observed when thymocytes were depleted of hydrocortisone (HC)-sensitive cells. It was concluded that SF selectively stimulate cAMP in HC-sensitive cells. Furthermore, incubation of thymocytes with SF enlarged the population of HC-resistant thymocytes. These results suggest that SF might act on HC-sensitive thymocytes increasing their cellular cAMP level and inducing their transformation in HC-resistant cells.

Animals↗
PubMed1977

Thymosin-induced human serum factor increasing cyclic AMP.

Thymosin has virtually no in vitro effect on cyclic AMP levels in thymocytes and seems not to react with either the beta-adrenergic receptor or with the putative human serum thymic factor (SF) receptor. However, when thymosin is injected into patients lacking SF activity, it induces the appearance of a serum factor which increases cellular cyclic AMP levels in thymocytes in vitro. This factor appears to act on a membrane site distinct from the beta-adrenergic receptors.

Animals↗
PubMed1976

In vitro reactivity of human lymphocytes after cryopreservation using a programmed cooling device.

In this article a technique is described for the cryopreservation of human lymphocytes employing a programmed cooling device. A preset temperature curve was used which compensated for the heat exchange during crystallization. The influence of this method of lymphocyte preservation on a variety of the in vitro functions of these cells was evaluated by means such as the lymphocyte transformation test, CML and investigations for lymphocyte membrane markers. All the lymphocyte functions that were tested were found to be retained in full.

Antibody-Dependent Cell Cytotoxicity↗
PubMed1976

Human lymphocyte subpopulations involved in MLC and CML.

Lymphocyte subpopulations from human peripheral blood were tested for their capacity to stimulate allogenic cells in MLC and for their ability to develop into cytotoxic cells in cell-mediated lympholysis (CML). By various cell separation experiments lymphocyte suspensions were depleted or enriched with respect to Fc receptor-bearing cells (detected as EA-RFC) and Ig-bearing cells. It was concluded that Fc receptor-bearing cells and Ig-bearing cells belong to different subpopulations. Furthermore, about 30% of the Fc receptor-bearing cells had T cell characteristics. The MLC stimulatory capacity was mainly confined to the Ig-bearing lymphocytes, and the Fc receptor-bearing cells and T cells exerted very little stimulation. Removal of Fc receptor-bearing cells strongly decreased the development of cytotoxic lymphocytes in CML. However, removal of Fc receptor bearing cells after MLC activation no longer affected cytotoxicity in CML. The activity in antibody-dependent lymphocytotoxicity was strongly decreased when Fc receptor-bearing cells were removed either before or after MLC activation. It was concluded that the cytotoxic precursor cells in CML bear an Fc receptor, which is either lost or blocked during MLC activation.

Binding Sites↗
PubMed1975

Antibody-dependent human lymphocytotoxicity: a micro assay system.

A micro assay system is described for measuring antibody-dependent lymphocytotoxicity with human effector cells. The target cells were mouse mastocytoma cells sensitized with rabbit antibody. The tests were performed in microtiter plates, each well containing 5 x 10(3) 51Cr-labeled target cells, together with varying numbers of effector cells. Whereas highly purified lymphocyte suspensions induced lysis, purified monocyte and granulocyte suspensions had virtually no effect. In parallel experiments it was shown that the latter cell suspensions were very active in lysing sensitized human erythrocytes, which in turn were not lysed by purified lymphocytes. Finally, it was shown that the lytic capacity of lymphocytes was not affected by preservation of the cells at liquid nitrogen temperature. It is concluded that the system described can be used for the clinical analysis of antibody-dependent lymphocytotoxicity in lymphocyte suspensions.

Animals↗